- Home
- SPCE vs MOLN Comparison
SPCE vs MOLN Comparison
Compare SPCE & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPCE | MOLN |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Transportation Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.1M | 137.2M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SPCE | MOLN |
|---|---|---|
| Price | $2.77 | $3.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $3.51 | ★ $10.22 |
| AVG Volume (30 Days) | ★ 5.6M | 1.9K |
| Earning Date | 11-12-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,544,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22,960.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.13 | $3.09 |
| 52 Week High | $8.90 | $5.36 |
Technical Indicators
Market Signals| Indicator | SPCE | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 53.97 | 33.33 |
| Support Level | $2.34 | N/A |
| Resistance Level | $3.31 | $4.21 |
| Average True Range (ATR) | 0.19 | 0.11 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 77.37 | 0.00 |
Price Performance
Historical ComparisonAbout SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.